USPTO 2015–2025 USPTO PatentsView Foreign Corporation

ThromboGenics NV

USPTO PatentsView assignee record - 9 granted patents across 10 technology areas, recorded in grant years 2015–2018. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

RSS updates for this company

The verdict

According to USPTO PatentsView, Thrombogenics ranks #30,414 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 10 technology areas.

#30,414
of 49,997 US assignees by volume
47th percentile
by Innovation Score (34.1/100)
28.1
avg claims per patent
-100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R30414 · Foreign Corporation #30,414 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

  • GRANTS-MICRO 9 grants
  • MID-PACK #30,414/49,997
  • PHOTO-FINISH Theralase
  • CPC-FOCUS A61K · 10 areas
  • INNOV-THIN 34.1/100
  • CLAIMS-DENSE 28.1 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-DROP -100% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Theralase Technologies Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Thrombogenics

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Thrombogenics's Innovation Score is 34.1/100 (47th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Thrombogenics's grants concentrate

ThromboGenics NV is a focused PatentsView assignee: 10 CPC subclasses with 88.9% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2015 (4 grants) versus a trough of 1 in 2018. By volume, Thrombogenics sits between Theralase Technologies Inc. and Tippmann Companies LLC.

Who files at ThromboGenics's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows ThromboGenics holds 9 patents at rank #30,409, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near ThromboGenics

By rank, the assignees closest to #30,409 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in ThromboGenics's primary technology class.

Thrombogenics's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

34 47th percentile higher than 47% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

012345 2015201620172018 1
USPTO utility patent grants by year · 2015–2018

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
ThromboGenics NV patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 4 44.4%
2016 2 22.2%
2017 2 22.2%
2018 1 11.1%

Where it ranks

Overall rank by patents

#30,414

of 49,997 tracked assignees

Innovation Score

34.1 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

ThromboGenics NV's patent record in context - here's where to go next.

  • ThromboGenics NV's lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 88.9% of its portfolio - see every assignee active in that class. Explore A61K
  • Ranked #30,414 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare ThromboGenics NV against Theralase Technologies Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 34.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.